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Abstract
Autoimmune pancreatitis is a relatively recently identified entity. The dominant 
type 1 is the pancreatic manifestation of a systemic IgG4-related fibroinflamma-
tory disease. The type 2 has a clearly different histology, its dominant feature is a 
granulocytic epithelial lesion, and it is independent of IgG4. While type 1 is rather a 
disease with male dominance in majors than 50-year-old people, no gender differ-
ence is observed in type 2, and the disease is more frequently seen in young people. 
The more frequent initial clinical manifestation is obstructive jaundice in type 1, 
while abdominal pain and mild acute pancreatitis in type 2. CT and magnetic reso-
nance images are very similar, IgG4 can be normal even in type 1, and the associated 
involvement of other organs is frequently posterior to the pancreatic manifestation; 
thus, the distinction of the two types of AIP can be difficult without histology in the 
everyday clinical practice. Several cases can be undetermined and qualified as Not 
Otherwise Specified (NOS). However, all types of AIP respond quickly to steroid 
treatment with a complete recovery. Late prognosis is good, but up to 50% recur-
rence has been observed in type 1, and several authors have described progression 
to chronic pancreatitis.
Keywords: autoimmune pancreatitis, IgG4-related disease, 
granulocytic epithelial lesion, histology, steroid treatment, complete recovery
1. Introduction
Autoimmune pancreatitis (AIP) is an emerging disease, recognized with an 
increasing frequency in the whole world. Autoimmune factors have been known 
since long time to participate in the etiology of some cases of chronic pancreatitis 
[1]; however, their importance was somewhat marginal, no more than 3–5% of 
the patients of chronic pancreatitis [2, 3]. In addition, pancreatic involvement 
is relatively rare in the major autoimmune diseases: while described, chronic 
pancreatitis is only exceptionally found in lupus erythematosus [4] and Sjögren’s 
syndrome [5, 6]. Conversely, AIP while described before [7, 8] was identified as an 
independent entity only in 1995 [9], and it is associated with specific IgG4-related 
autoimmune disease (type 1) and with inflammatory bowel disease (type 2). 
Their histology is characteristic and quite different when compared to pancreatic 
involvement in SLE or Sjögren’s syndrome. This fact is very similar to the case of 
the liver, hepatitis associated with lupus and autoimmune hepatitis being also the 
two distinct diseases [10].
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2. Definition, classification, and histology
The concept of autoimmune pancreatitis was introduced by Yoshida in 1995 [9] 
and accepted worldwide. The majority of cases initially described came from Asia, 
but later on the disease was recognized in the whole world. With the exponentially 
growing information, two different forms were distinguished: the type 1 or lympho-
plasmacytic sclerosing pancreatitis (LPSP) and the type 2 or idiopathic duct-centric 
pancreatitis. Type 1 has been dominant in the whole world and represents the most 
frequent digestive manifestation of a systemic fibroinflammatory IgG4-related dis-
ease. Its histology is characteristic: the association of storiform fibrosis, obliterative 
phlebitis, and marked lymphoplasmacytic infiltration are unique, and the immuno-
histology can be the final proof, demonstrating the presence of more than 40% of 
IgG4-positive lymphocytes as compared to the whole number of IgG-positive cells. 
Details of the autoimmune reaction are well described, but the whole process is not 
known. Circulating plasmablasts are present in increased number in the active phase 
of the disease and decrease rapidly with the treatment [11]. Interaction of T- and B 
lymphocytes has been demonstrated. Th2 reaction and regulator T-cell activation 
are part of the process, resulting from one part in an increase of interleukins 4, 5, 
and 13 with a consecutive increase of eosinophils and serum IgE and from the other 
part increased IL-10 production, lymphoplasmacytes, and fibroblast proliferation, 
with an increased IgG4 level. As these diseases are recognized as IgG4-related, one 
could expect IgG4 lymphoplasmacytes as key factors inducing the immune reac-
tion and organ damage. However, the characteristics of the IgG4 subclass do not 
permit complement activation or immune complex formation. Both IgG4 and IgG1 
obtained from an active AIP patient, when injected separately, induced pancreatic 
damage in experimental design. However, when injected simultaneously, IgG4 was 
rather protective and reduced the IgG1-induced pancreatic damage [12]. Based 
on these experimental data, IgG1 subclass seems to be more active in producing 
damage, and the local increase of IgG4 cells and elevated serum IgG4 level seems 
to be rather a consequence. In type 2, AIP has a clearly different histology. The 
fibrosis is important, but not storiform, phlebitis/venulitis is rare, and if present, 
it is not obliterative. The essential finding is infiltration by neutrophil leucocytes, 
forming the typical granulocytic epithelial lesion (GEL), with duct cell damage. 
Similar lesions can also be observed in pancreatic lobules. While lymphoplasmacytic 
infiltration can exist, IgG4-positive cells are rare. A unique finding in type 2. AIP is 
the presence of IL-8 around the ductal cells, in particular in the damaged pancreatic 
ducts. IL-8 is a chemotactic factor for neutrophils, and its high expression is in 
line with the formation of granulocytic epithelial lesions [13]. In addition, similar 
accumulation of IL-8 was described in the damaged mucosa of ulcerative colitis but 
not in other types of colitis. This finding points out a similarity in pathomechanism 
of these diseases as a possible explanation of the well-known association.
2.1 Autoantibodies: serology
Several autoantibodies were described in AIP, against carbonic anhydrase [14] 
and amylase [15], but they do not have any demonstrated role in the initiation of the 
autoimmune process. A cross-reaction was found against a protein of Helicobacter, 
the plasminogen-binding protein [16], but its role in the pathogenesis of AIP was 
not confirmed. Unspecific autoantibodies, as antinuclear and anti-DNA, can also 
be present. A variety of autoantibodies have been found in the sera of patients with 
AIP, but none of these autoantibodies appear to be disease specific. The serum IgG4 
level has been found elevated in a variable proportion of confirmed type 1 AIP 
cases. Sensitivity above 80% was published in some papers, while others found only 
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<50% [17]. On the contrary, IgG4 can be elevated even in some cases of pancreatic 
cancer. Once increased, the serum IgG4 level is a useful marker in confirming the 
diagnosis of AIP type 1, but a normal value does not exclude AIP. Unfortunately, no 
specific test exists even for the diagnosis of AIP type 1, and type 2 is not accompa-
nied by laboratory alterations. In our experience [18], we found IgG4 > 135 mg% 
in 80% of confirmed AIP type 1 cases but in none of 20 NOS undetermined cases, 
while several of these patients, if not the majority of them, were probably seronega-
tive type 1. It means that the real diagnostic performance was far less than 80% in 
our clinical practice, even considering a lower cutoff value.
3. Epidemiology and clinical characteristics
AIP is increasingly recognized. For example, 900 cases were known in Japan 
in 2002 [19]; 2790 in 2007 [20]; and 5745 in 2011 [21]. The calculated prevalence 
was 4.6/100,000, while the incidence 1.4/100,000/yr. Experiences from different 
regions of the world have been increasingly published; the annual number of papers 
increased exponentially from 39 in 2000 to 935 in 2017, as found in PubMed Central. 
We also observed a marked increase in the diagnosis of AIP in Chile [18]. However, the 
worldwide increase in the frequency of this disease is probably mainly due to its better 
recognition rather than a-so-important increase in incidence. The more frequent type 1 
AIP is part of a systemic IgG4- related disease. A male dominance has been observed; 
about two thirds of patients are men. The average age is above 50 years. However, 
there are also women in considerable number. The pancreatic affection is frequently 
associated with manifestation of the same disease in other organs. Recurrence in the 
pancreas or in other organs is relatively frequent in this form. Type 2 AIP has been 
described later, but it is also recognized with a growing frequency. No gender differ-
ence was described, and the disease affects young people; the mean age is no more 
than 30 years. The only associated disease is inflammatory bowel disease (IBD), 
mainly ulcerative colitis, which can occur simultaneously with the pancreatitis or any 
other period, before or after the AIP. This form of pancreatitis seldom recurs (Table 1)
4. Diagnosis
4.1 Clinical symptoms
The clinical manifestation of AIP is variable and non-specific. The most 
frequent symptom is painless jaundice due to compression of intrapancreatic 
Type 1 (LPSP) Type 2 (IDCP)
Sex Male dominance (two to three times) No difference
Age After fifth decade Young people, <30
Dominant symptom Jaundice Pain, mild pancreatitis
Serum IgG4 level Frequently increased (50–80%) Normal
Associated diseases IgG4-related organ involvement Inflammatory bowel disease
Response to steroids Quick, complete Quick, complete
Relapse >30% Rare, <10%
LPSP, lymphoplasmacytic sclerosing pancreatitis; IDCP, idiopathic duct-centric pancreatitis.
Table 1. 
Clinical characteristics of two types of autoimmune pancreatitis.
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segment of choledochus by the fibroinflammatory process in the pancreatic head. 
Unfortunately, it shares typical symptoms of pancreatic head cancer and represents 
one of the most challenging difficulties in differential diagnosis. Abdominal pain 
and mild acute pancreatitis are also important manifestations. However, severe 
acute pancreatitis and major local fluid collections practically do not occur and 
autoimmunity is not a frequent cause of recurrent acute pancreatitis.
4.2 Serology
As described above, the only valuable serological marker is the serum IgG4 level 
[17]. However, its performance in the diagnosis is variable: it can be increased only 
in type 1, not in type 2. Other unspecific autoantibodies have low sensibility in 
AIP and are not used routinely. Sometimes, IgE and peripheral eosinophils can be 
increased. If altered, they help in the diagnosis; if not, they have no value in exclud-
ing it.
4.3 Images
Radiologic exams, CT scan, and MR are the bases of the diagnosis in the 
everyday clinical practice [22]. Typical sausage-like increase in pancreatic size 
with a peripheral halo is seen in several cases when the pancreas is diffusely 
affected. Frequently, only segments of pancreas are involved. In these cases the 
differences in density or signal intensity as compared to the normal segments 
(Figures 1b, 2b and 3a,b), the late enhancement with contrast, and the irregular 
stricture of the main pancreatic duct can be helpful. In the difficult situation when 
there is a clinical suspicion of pancreatic cancer, even without a clear-cut mass, 
the absence of significant upstream duct dilation is an important element which 
Figure 1. 
(a) Magnetic resonance cholangiography showing pancreatic duct stricture in the head and stenosis of 
intrapancreatic segment of choledochus with proximal dilatation. Pancreatic duct is only slightly dilated in 
the body and tail. (b) Pancreatic head is enlarged with slightly hyperintense signal in T2. The pancreatic duct 
is only seen in the body and tail. (c and d) The same patient and same images after 2 months of treatment. 
Almost complete recovery, with slight pancreatic atrophy. The images of this chapter come from the Radiolology 
Department of Clinical Hospital of University of Chile and are the authors’ property.
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helps to distinguish the two pathologies with diametrically different prognoses 
(Figures 1a,b, 2a,b  and 5a). It is noteworthy that neither necrosis nor major peri-
pancreatic fluid collection are seen in AIP. Sometimes, pseudocysts can complicate 
the disease [23]; they also respond to steroids and can disappear even completely. It 
is important to emphasize that there is no difference in the radiologic alterations in 
types 1 and 2 of AIP.
4.3.1 When to perform diagnostic ERCP and biliary drainage?
The necessity of ERCP in order to establish the diagnosis of AIP nowadays is an 
exception. Magnetic resonance images have a similar sensibility in the diagnosis. If 
performed, irregular and usually multifocal narrowing of the main pancreatic duct 
is seen in the affected pancreatic segment, without an important upstream dilatation 
(Figure 5a). Stenosis of intrapancreatic segment of choledochus is frequent, and, 
sometimes, irregular strictures of extra- and intrahepatic bile ducts can show the 
associated IgG4-related cholangitis, very similar to the primary sclerosing cholan-
gitis (PSC) (Figures 5b and 6a). The clinical need of ERCP is determined in the 
majority of the cases by the severe obstructive jaundice and the intention to drain 
the obstructed dilated bile duct with a biliary endoprosthesis (Figures 5b and 6b). 
However, it is at least a matter of discussion: the decrease in bilirubin level in 
response to steroid treatment is strikingly rapid, and it seems better to avoid unnec-
essary instrumentalization of biliary tract with the risk of bacterial contamination. 
Once ERCP is performed without the previous suspicion of AIP and contrast mate-
rial injected in the obstructed bile duct, stent placement is mandatory as in any other 
causes of bile duct obstruction. In our practice, we performed ERCP only in our first 
Figure 2. 
(a) Markedly dilated choledochus, proximal to the stenotic intrapancreatic segment of the bile duct. Irregular 
multiple stenosis of the main pancreatic duct. (b) Again, the structured pancreatic duct is practically not seen 
in the augmented pancreatic head, but the upstream dilatation is only mild.
Figure 3. 
Focal AIP in the pancreatic tail. (a) T2, hyperintensity of the signal; (b) T1, hypointense signal. Arrow: the 
swollen pancreatic segment. Pointed arrow: normal pancreas. Note the clear limitation between the normal and 
involved segments.
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patients, later on only in some exceptional cases when even concomitant sclerosing 
cholangitis was not excluded, and it was impossible to avoid biliary stent placement. 
In fact, Chari’s group published the same tendency from Mayo Clinic [24].
4.4 Other organ involvement
A type 1 AIP is a systemic disease; we can see frequently signs of the disease in 
other organs. Fibroinflammatory tumor-like pathology of lacrimal and salivary 
glands is clearly visible, palpable, and easy to access for a biopsy. However, other 
manifestations, as frequent bilateral nephritis, can be asymptomatic but easily 
detectable on the MR image (Figure 4a), frequently synchronic with the pancreatic 
disease. Peritoneal fibrosis and aortitis can occur in different times, before or later, 
as compared to AIP. In our experience PSC like cholangitis and bilateral multifo-
cal nephritis were the most frequent extrapancreatic manifestations, found in 8 
and 11 of our 44 type 1 patients, respectively [18]. Any of these manifestations, in 
particular when their histology confirms IgG4-related disease, can be considered as 
a definitive proof for type 1 AIP. For type 2, the association of IBD makes probable 
the diagnosis, but cannot be considered as a definitive proof.
4.5 Histology
Histology is a definitive diagnosis. Unfortunately, in the everyday clinical prac-
tice, the access to an adequately evaluable biopsy sample is not easy. Characteristic 
Figure 4. 
(a) Nephritis in IgG4-related, type 1. AIP, concurrent with pancreatitis. Arrow: involved renal areas. 
(b) Primary sclerosing cholangitis like simultaneous extra- and intrahepatic biliary tract lesions. Arrows: bile 
duct strictures. Pointed arrow: pancreatic duct stricture.
Figure 5. 
ERCP of a patient. (a) Long stricture of pancreatic duct in the head (arrow), with a moderate upstream 
dilatation in the body and tail. (b) Bile duct stricture in the same patient (arrow).
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histology is easily seen in a surgically resected pancreas [25]. However, this is too 
late for the patient, who could have been treated safely with steroids instead of a 
major surgery. Percutaneous pancreatic biopsy made by interventional radiologists 
has some risks and not a currently used method. Endosonography (EUS)-guided 
biopsy would be the recommended way to obtain pancreatic tissue. EUS image itself 
is even somewhat superior to MR and gives valuable information in the differential 
diagnosis. In addition, fine-needle aspiration by EUS is the safest way to obtain 
pancreatic cytology. However, cytology has a good performance in the diagnosis of 
pancreatic cancer but not in the diagnosis of AIP, this latter requiring a real tissue 
sample biopsy [26–28].
4.5.1  When to perform EUS and FNA? Value of cytology and biopsy in differential 
diagnoses.
Diagnosis of type 1 AIP can be made with high certainty in many patients: 
clinical symptoms, characteristic images supported by elevated serum IgG4 level, 
and other organ involvement can assure the diagnosis without pancreatic histol-
ogy. However, in the absence of these latter conditions, establishing the definitive 
diagnosis of even type 1 AIP can be difficult. In type 2 AIP, IgG4 is practically never 
increased, and IBD is the only associated pathology, but only probable diagnosis can 
be done without histology. With the availability of new biopsy needles (shark, core 
biopsy), which permit to obtain a small tissue cylinder, diagnostic performance of 
pancreatic biopsy has dramatically increased, without major risk of complications: 
clinically significant hemorrhage and pancreatitis are rare, below 1%. Thus, biopsy 
should be considered in every patient with a suspicion of seronegative type 1 and in 
type 2 AIP, preferably before initiating a relatively long steroid treatment.
4.6 Response to glucocorticosteroid treatment
The improvement in the pancreatic morphology in response to steroid treat-
ment is very quick, easily detectable already after 2 weeks. This fact can be used 
even in the differential diagnosis: while AIP improves rapidly, pancreatic cancer 
evidently does not respond to steroids, and no change in the pancreatic morphol-
ogy can be observed after 2 weeks. In addition, it was demonstrated by Moon et al. 
[29] that the “lost” 2 weeks did not change the resectability of the malignant lesion. 
This short treatment trial is only acceptable if a good biopsy is not available or the 
histologic finding is uncertain in a patient of high surgical risk. It means that steroid 
treatment trial has to be restricted to the cases, when:
Figure 6. 
ERCP of another patient. (a) Multiple stenotic segments in the bile duct: a long stricture is observed in the 
distal half of choledochus (arrow) and a shorter stenosis in the hepatic hilum (pointed arrow). (b) Stent 
(arrow) placement in the bile duct.
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• EUS and pancreatic biopsy is not available or its result is uncertain.
• Conditions of very strict and early control are assured.
• The patient is known and followed by a multidisciplinary group.
• If there is no clear improvement after 2 weeks of treatment, steroids are 
withdrawn and the patient goes to surgery.
In conclusion, in the everyday clinical practice, the basis of the diagnosis 
is radiology, showing typical characteristic images of the pancreas (Table 2). 
However, differential diagnosis is not always easy and other parameters could be 
of utility. Unfortunately, no specific autoantibodies have been discovered till now. 
Increased, >270 mg/dl serum IgG4 level seems to be quite specific but not enough 
sensitive in the diagnosis of type 1 AIP, and IgG4 has no value in type 2. Other 
organ involvement can be useful again in the diagnosis of type 1 AIP. In addition, 
imaging alterations do not distinguish between type 1 and type 2. Thus, type 2 AIP 
almost always requires biopsy and histology; in its absence the diagnosis can be 
only highly probable but not definitive [30]. Type 1 AIP can be definitely dem-
onstrated without biopsy in the majority of cases. However, several patients have 
an undetermined AIP, which is named NOS [31], a mixture of seronegative type 1 
and possible type 2 cases. A useful simple algorithm in the differential diagnosis is 
proposed in Figure 7.
After the diagnosis of AIP, the classification has practical and prognostic 
significance. As described above, characteristic image on MRI associated with 
serum IgG4 level more than double of upper limit of normal (>270 mg%) and/
or simultaneous or sometimes previous presence of IgG4-related disease in other 
organs are sufficient to establish definitive diagnosis of type 1 AIP, even without 
histology. If IgG4 is normal and the only associated disease is ulcerative colitis or 
Crohn’s disease, the classification in type 2 AIP is probable, but not definitive. If 
the patient does not have any associated disease, only NOS AIP is the clinically 
Increase in size Dilatation of ducts Parenchyma Neighborhood
Acute 
pancreatitis
Diffuse No Edema +/− necrosis Fluid 
collections
Chronic 
pancreatitis
Focal Diffuse, irregular Atrophy 
+/− calcifications
—
Groove 
pancreatitis
Head, groove Upstream, regular Normal —
Autoimmune 
pancreatitis
Focal or diffuse Stricture +/− slight 
upstream dilatation
Altered signal, 
contrast 
enhancement and 
diffusion
—
Pancreatic 
cancer
Focal 
(hypovascular 
mass)
Marked upstream Upstream atrophy Metastasis in 
lymph nodes
Note the unique combination of findings in autoimmune pancreatitis. The absence of more significant upstream 
dilatation of pancreatic duct and altered signal in the parenchyma, both useful as compared to pancreatic cancer. On 
the other hand, the absence of necrosis and peripancreatic fluid collections helps to distinguish it as compared to acute 
pancreatitis.
Table 2. 
Characteristic alterations in pancreatic and peripancreatic morphology, useful in the differential diagnosis.
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Figure 7. 
A simplified algorithm for the differential diagnosis and treatment of autoimmune pancreatitis. Briefly: Once 
AIP is suspected on the basis of medical history or abdominal US findings, CT scan or MRI is performed, of 
course completed with determination of the IgG4 level in the serum. These data can be sufficient to establish 
definitive diagnosis of AIP or pancreatic cancer and initiate proper treatment. The effect of steroid treatment 
must be confirmed after a short time, about 2 weeks: if no improvement is detectable, the diagnosis of AIP 
is improbable, and the patients must be reevaluated for surgery or at least biopsy. If the initial workup gives 
an equivocal result, EUS and biopsy (not cytology!) is necessary to define the diagnosis and treatment. CT, 
computed tomography; MRI, magnetic resonance imaging; EUS, endosonography; Cht, chemotherapy.
Figure 8. 
Classification of AIP in different subclasses. Type 1 can be frequently demonstrated without histology, while 
definitive diagnosis of type 2 requires biopsy in the majority of cases. NOS is clinically a useful category, in 
particular, when no biopsy is available. For details, see text. LPSP, lymphoplasmacytic sclerosing pancreatitis; 
GEL, granulocytic epithelial lesion; NOS, Not Otherwise Specified; IBD, inflammatory bowel disease.
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possible diagnosis. In these latter cases, pancreatic biopsy is advisable, guided by 
EUS and taking core biopsy, not cytology. Several cases will show typical histol-
ogy of type 1 AIP. In others, the absence of significant IgG4-positive lymphoplas-
macytic infiltration and the presence of granulocytic epithelial lesions with or 
without neutrophil infiltration of the pancreatic lobules prove definitively type 2 
AIP. However, typical histological features of type 2 can be also absent in the core 
biopsy: in these cases the diagnosis continues to be NOS or sometimes probable 
type 2 (Figure 8).
5. Treatment
Once the diagnosis of AIP is established, treatment with steroids should 
be started. While some tendency to spontaneous improvement can exist in 
several cases, steroid treatment is far superior, and the recovery of pancreatic 
involvement is almost always complete after a relatively short, some month of 
treatment [32, 33]. The widely accepted dose of prednisone is relatively low, 
about 0.5–0.6 mg/kg/day. Others initiate the treatment with 40 mg prednisone/
day. After 3–4 weeks with this treatment, the steroid dose is tapered, reducing it 
5 mg/day every 2 weeks. Finally, the treatment can be stopped after the com-
plete morphological recovery demonstrated by CT scan or magnetic resonance. 
However, some authors argue in favor of a maintenance treatment with pred-
nisone in a dose as low as 5 mg/day for 2 years, and they found less recurrence 
with this conduct, but it is impossible to avoid completely the recurrence of 
the disease in the pancreas or in some other organ. The recurrent disease also 
responds to steroid treatment. However, in case of recurrence, it is advisable 
to initiate a longer treatment with some steroid-sparing agent, azathioprine 
(1.0–1.5 mg/kg/day) or mycophenolate (2 to 3 g/day) for several years. If these 
treatments fail, rituximab has been shown effective in the treatment of the 
first episode of the disease and also in its recurrence. In our experience, steroid 
treatment with or without steroid-sparing agents was effective in all but one 
cases; we recently used rituximab 1000 mg repeated in 15 days, i.e., 2000 mg as 
total dose, in one exceptional patient, with a good initial result. The Mayo Clinic 
experience [34] is in favor to repeat rituximab 1000 mg every 2–6 months and 
use it as maintenance treatment. Diabetes becomes frequently clinically overt 
during the acute phase, as a consequence of the disease itself and the effect of 
corticosteroids. Insulin treatment can be necessary, but it is transitory in the 
majority of the patients. Close control is mandatory in order to adjust the insulin 
dose, which changes rapidly during the treatment: insulin requirement initially 
increases and later on decreases rapidly. Clinically evident pancreatic exocrine 
insufficiency during the acute phase is not observed; enzyme supplementation is 
not necessary.
The effect of steroids is uniformly excellent. It means that if steroids fail to 
induce remission, one must have serious doubts in the diagnosis, whatever was the 
basis to establish it. In these cases histological diagnosis is mandatory and surgery 
is probably inevitable. In spite of the growing knowledge about AIP, the differential 
diagnosis can be difficult, and AIP continues to be a histological finding of some 
patients operated on with the suspicion of pancreatic cancer. However, surgery is 
not a good treatment for AIP; the recurrence without prednisone treatment con-
tinues to be a real possibility. In addition, pancreatic resection has surgical morbi-
mortality and late metabolic consequences, which are hardly justifiable in a benign 
medically treatable disease.
11
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6. Late prognosis: progression to chronic pancreatitis
AIP has been considered as a subclass of chronic pancreatitis (CP). There is no 
doubt that autoimmune factors can have some importance of the pathogenesis of 
CP and also in some cases of recurrent acute pancreatitis (RAP). There is also a 
possibility that the idiopathic advanced CP in several cases can be the late conse-
quence of unrecognized and untreated AIP. However, clinical and epidemiological 
characteristics; morphological alterations in CT, MR, and EUS; images and histol-
ogy are all quite different when compared to CP [35]. In addition, CP is a progres-
sive damage to the pancreas, while AIP is a reversible disease after an adequate 
treatment. There are contradictory observations in the literature about the long-
term outcome of AIP [36–38]. When we evaluate the published observations, we 
must be cautious, and we have to remember that AIP was definitively described 
only in 1995; it means that follow-up of patients for a period longer than 20 years 
is lacking. Biliary stenting by ERCP [39] and significant focal stenosis of the main 
pancreatic duct [40] were found as risk factors for formation of pancreatic stones 
and progression to CP. Exocrine and endocrine insufficiencies were described in a 
significant number of patients [41], even without detectable changes of advanced 
pancreatic disease. However, pancreatic enzyme replacement therapy has not 
been routinely used even in these cases. Our limited experiences are different: 
while 11 of our 74 patients had diabetes, clinically overt exocrine insufficiency was 
observed only in 2 of them [18], requiring oral pancreatic enzyme replacement 
therapy. We can find similar doubts in the literature about the risk of malignancy: 
higher incidence of pancreatic and extrapancreatic cancer was described by some 
authors [42] but not confirmed by others [43]. We did not observe malignant 
disease in our cohort of patients.
The possibility of AIP to PC requires longer observations. However, we insist 
that AIP in our opinion is not a simple subclass of CP. The differences are as strong 
as or even stronger than in the case of obstructive pancreatitis. Both of these entities 
can be reversible with an adequate timely treatment, and probably both of them can 
progress to CP if their cause persists unresolved [44]. If it is true, it underlines even 
more the importance of the early diagnosis and proper treatment.
7. Conclusions
Autoimmune pancreatitis is an increasingly recognized, relatively new disease, 
identified definitively only in 1995. Two types of the AIP are described, type 1 or 
lymphoplasmacytic sclerosing pancreatitis (LPSP) and type 2 or idiopathic duct-
centric pancreatitis. While type 1 is part of an IgG4-related systemic disease, type 2 is 
limited to the pancreas and can be associated only with inflammatory bowel disease. 
The diagnosis is not easy; detection of morphological alterations is the clue in recog-
nizing AIP and distinguishing it from other pancreatic diseases. Once the diagnosis 
is made, the clinical classification of types 1 and 2 also can be difficult. For this 
reason, an indeterminate category Not Otherwise Specified (NOS) is useful in the 
everyday clinical practice. All types of AIP respond rapidly and completely to steroid 
treatment. The late prognosis is good, but residual morphological and functional 
pancreatic changes can be present. Progression to advanced CP probably can be pre-
vented with adequate treatment. These characteristics make AIP a unique pancreatic 
disease: its correct diagnosis avoids unnecessary surgery, and it is the only pancreatic 
disease when we have the possibility to achieve a complete recovery with noninvasive 
medical treatment. It is particular also among the autoimmune diseases: an excellent 
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